MRPL36 Antibody

What is MRPL36 and what is its role in mitochondrial function?

MRPL36 (Mitochondrial Ribosomal Protein L36) is a 103 amino acid protein that localizes to the mitochondrion, where it functions as a component of the 39S ribosomal subunit. It works in conjunction with other mitochondrial ribosomal proteins to mediate protein synthesis within the mitochondrion . Research indicates that MRPL36 plays a critical role during translation that determines the rate of respiratory chain assembly, specifically through its stabilizing activity on the interaction between large and small ribosomal subunits, which influences the accuracy of protein synthesis . This makes it an important target for studies focused on mitochondrial function and biogenesis of respiratory chain complexes.

What are the key structural domains of MRPL36 and their functional significance?

MRPL36 consists of three distinct structural domains, each with specific functions:

• An N-terminal mitochondrial targeting sequence that is proteolytically removed in the matrix upon import

• A conserved domain similar to bacterial L31, which is necessary for respiratory and translational activity of mitochondria

• A mitochondria-specific C-terminal extension domain (CE domain) that is absent in bacterial L31 proteins

The L31 domain is essential for basic respiratory and translational activity, while the CE domain, though dispensable for respiratory activity, appears to play a role in translational regulation. Notably, genetic analyses have shown that even when expressed alone, the CE domain was sufficient to suppress defects of specific cox2 mutants .

How should I select the appropriate MRPL36 antibody for my specific experimental application?

Selection of the appropriate MRPL36 antibody should be based on several factors:

• Target application: For immunohistochemistry (IHC), consider antibody 16625-1-AP, which has been validated for human tissue samples at dilutions of 1:20-1:200 . For Western blotting, ABIN2790654 offers broad species reactivity and C-terminal specificity .

• Target species: If working with non-human models, ABIN2790654 offers the broadest reactivity across multiple species including mouse, cow, and even yeast models .

• Domain-specific studies: For studies focusing on specific domains of MRPL36, select antibodies targeting relevant regions - AA 2-103 (ABIN6078093) for N-terminal studies or C-terminal specific antibodies (ABIN2790654) for examining the CE domain's role .

• Detection method: For fluorescence-based detection, consider FITC-conjugated antibodies like ABIN6078093 . For enzymatic detection in ELISA or standard visualization in Western blots, unconjugated antibodies are suitable.

It is recommended that each antibody be titrated in your specific testing system to obtain optimal results, as performance can be sample-dependent .

What are the optimal storage conditions for MRPL36 antibodies to maintain activity?

MRPL36 antibodies should generally be stored at -20°C, where they remain stable for approximately one year after shipment . Specific storage recommendations include:

• For antibody 16625-1-AP: Store in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. Aliquoting is unnecessary for -20°C storage. Note that 20μl size preparations contain 0.1% BSA .

• For FITC-conjugated antibodies (ABIN6078093): These are typically stored in 0.01 M PBS, pH 7.4, with 0.03% Proclin-300 and 50% Glycerol as a preservative .

• Prior to experimental use, allow antibodies to reach room temperature completely before opening to prevent condensation that could affect antibody stability and performance.

What positive and negative controls should be included when using MRPL36 antibodies?

For robust experimental design with MRPL36 antibodies, the following controls should be considered:

Positive controls:

• For IHC applications: Human testis tissue and human colon tissue have been validated as positive controls for MRPL36 antibody 16625-1-AP .

• For Western blotting: Mitochondrial fractions from human cell lines known to express MRPL36.

Negative controls:

• Antibody diluent without primary antibody to assess non-specific binding of secondary antibodies.

• Samples from MRPL36 knockout models where available.

• Pre-incubation of the antibody with the immunizing peptide to demonstrate specificity.

• Non-mitochondrial fractions (cytosolic proteins) should show minimal to no detection.

When validating a new antibody, it is advisable to compare results with another validated antibody targeting a different epitope of MRPL36 to confirm specificity .

How can MRPL36 antibodies be used to investigate the dynamics of mitochondrial ribosome assembly?

MRPL36 antibodies offer powerful tools for investigating mitochondrial ribosome assembly dynamics through several sophisticated approaches:

• Co-immunoprecipitation studies: Using MRPL36 antibodies to pull down associated ribosomal complexes can reveal interaction partners and assembly intermediates. Research has shown that Mrpl36 associates with mitochondrial ribosomes in a dynamic manner and contributes to the interaction between both ribosomal subunits . This approach can help elucidate how MRPL36 mediates these interactions.

• Gradient fractionation combined with Western blotting: Sucrose or glycerol gradient fractionation of mitochondrial extracts followed by Western blotting with MRPL36 antibodies can track the protein's association with different ribosomal assembly intermediates. This methodology has revealed that MRPL36 plays a role in stabilizing the interaction between large and small ribosomal subunits .

• Proximity labeling techniques: Combining MRPL36 antibodies with proximity labeling methods like BioID can identify transient interaction partners during ribosome assembly, providing temporal information about the assembly process.

• Super-resolution microscopy: Using fluorescently conjugated MRPL36 antibodies (such as FITC-conjugated ABIN6078093) for super-resolution imaging can visualize the spatial organization of MRPL36 within mitochondrial ribosomes and track changes during assembly .

For these advanced applications, it is crucial to validate antibody specificity through multiple approaches and consider domain-specific antibodies to distinguish different functional aspects of MRPL36 .

What methods can be used to study the role of MRPL36 in coordinating nuclear and mitochondrial gene expression?

MRPL36's position as a nuclear-encoded component of mitochondrial ribosomes makes it an excellent target for studying nuclear-mitochondrial coordination. Several methodological approaches include:

• Chromatin immunoprecipitation (ChIP) combined with mitochondrial translation assays: This approach can correlate nuclear transcriptional regulation of MRPL36 with subsequent effects on mitochondrial protein synthesis.

• Pulse-chase labeling of mitochondrial translation products: In models with modified MRPL36 expression, this technique can assess how MRPL36 levels affect the synthesis and stability of mitochondrially-encoded proteins. Research has shown that deletion of the CE domain leads to decreased stability of translation products and severe defects in respiratory chain complex biogenesis .

• RNA immunoprecipitation (RIP): Using MRPL36 antibodies for RIP can identify mitochondrial mRNAs associated with MRPL36-containing ribosomes, providing insights into potential transcript-specific functions.

• Dual fluorescence reporter systems: Combining reporters for nuclear MRPL36 expression and mitochondrial translation activity can reveal temporal relationships between these processes.

• Comparative proteomics: Comparing the mitochondrial proteome in wild-type versus MRPL36-deficient or MRPL36-overexpressing cells can identify the broader impact of MRPL36 on coordinating nuclear and mitochondrial gene expression .

These methods can be particularly powerful when combined with genetic approaches that specifically modify the different domains of MRPL36, as research has shown distinct functions for the L31 domain versus the mitochondria-specific CE domain .

How can I investigate the role of MRPL36's C-terminal extension domain in translational regulation?

The C-terminal extension (CE) domain of MRPL36 presents a particularly interesting research target as it is mitochondria-specific and has been implicated in translational regulation. Methodological approaches include:

• Domain-specific antibody applications: Using C-terminal specific antibodies like ABIN2790654 to specifically track the CE domain in various experimental contexts .

• Domain deletion studies: Creating experimental models expressing MRPL36 lacking the CE domain (MRPL36ΔC) and assessing effects on:

  • Stability of MRPL36 itself (shown to decrease without the CE domain)

  • Folding and assembly of translation products

  • Degradation rates of mitochondrial translation products

  • Respiratory chain complex formation

• Domain swapping experiments: Replacing the CE domain with heterologous domains to identify specific sequence elements required for its function.

• Suppressor screening: As MRPL36 was identified as a high-copy suppressor of specific cox2 mutants, systematic screening with CE domain variants can map functional regions within this domain .

• Structural studies: Using purified MRPL36 with intact or modified CE domains for structural analysis (X-ray crystallography or cryo-EM) to determine how this domain influences ribosome structure.

Research has demonstrated that while deletion of the CE domain does not affect protein synthesis per se, it leads to decreased amounts of MRPL36 and inhibits productive folding and assembly of translation products, resulting in rapid degradation and severe defects in respiratory chain complex biogenesis .

What are common issues when using MRPL36 antibodies for immunohistochemistry and how can they be resolved?

When utilizing MRPL36 antibodies for immunohistochemistry (IHC), researchers may encounter several challenges. Here are common issues and their solutions:

• Weak or absent signal:

  • Solution: Optimize antigen retrieval methods. For antibody 16625-1-AP, suggested antigen retrieval includes TE buffer at pH 9.0 or alternatively citrate buffer at pH 6.0 .

  • Solution: Adjust antibody concentration. For 16625-1-AP, recommended dilutions range from 1:20 to 1:200, but optimal concentration should be determined empirically for each tissue type .

  • Solution: Extend primary antibody incubation time or perform at 4°C overnight.

• High background staining:

  • Solution: Include additional blocking steps with BSA or serum.

  • Solution: Ensure proper washing between steps.

  • Solution: Decrease primary antibody concentration.

  • Solution: Use more specific detection systems.

• Non-specific staining:

  • Solution: Validate antibody specificity using tissues from MRPL36 knockout models or with siRNA knockdown controls.

  • Solution: Include peptide competition controls where the antibody is pre-incubated with the immunizing peptide.

• Inconsistent results across samples:

  • Solution: Standardize fixation protocols as overfixation can mask epitopes.

  • Solution: Ensure consistent tissue processing and storage conditions.

  • Solution: Include positive control tissues (human testis or colon tissue have been validated) .

For optimal results with MRPL36 antibodies in IHC applications, it is recommended to titrate the antibody in each specific testing system as performance can be sample-dependent .

How can I optimize Western blot protocols when using MRPL36 antibodies for detection of mitochondrial ribosomal proteins?

Optimizing Western blot protocols for MRPL36 (a relatively small protein at 12 kDa) requires attention to several specific factors:

• Sample preparation:

  • Ensure proper mitochondrial isolation to enrich for MRPL36, as it is exclusively localized to mitochondria.

  • Use protease inhibitors during extraction to prevent degradation.

  • Consider using specialized mitochondrial protein extraction buffers that maintain the integrity of mitochondrial complexes.

• Gel selection and running conditions:

  • Use higher percentage gels (15-20%) or gradient gels to better resolve the 12 kDa MRPL36 protein .

  • Consider using Tricine-SDS-PAGE systems which are optimized for small proteins.

  • Run gels at lower voltage to improve resolution of small proteins.

• Transfer optimization:

  • Use PVDF membranes with smaller pore sizes (0.2 μm) to prevent small proteins from passing through.

  • Consider semi-dry transfer systems which can be more efficient for small proteins.

  • Use transfer buffers with lower methanol content and adjust transfer time and voltage.

• Antibody selection and dilution:

  • For Western blotting applications, ABIN2790654 (C-Term) has been specifically validated .

  • Start with manufacturer's recommended dilutions and optimize based on signal-to-noise ratio.

• Detection system:

  • Consider using more sensitive detection systems like enhanced chemiluminescence (ECL) or fluorescence-based detection.

  • For mitochondrial proteins that may be less abundant, avoid stripping and reprobing membranes as this can reduce sensitivity.

• Controls:

  • Include mitochondrial fraction controls from cells with known MRPL36 expression.

  • Consider including recombinant MRPL36 protein as a positive control.

Research has shown that MRPL36 levels can change based on experimental conditions, particularly when the CE domain is deleted, so quantification should be performed carefully with appropriate loading controls .

What strategies can address cross-reactivity issues when studying MRPL36 in different species?

When studying MRPL36 across different species, addressing potential cross-reactivity issues requires strategic approaches:

• Antibody selection based on sequence conservation:

  • ABIN2790654 offers the broadest species reactivity, with predicted reactivity percentages across multiple species: Human (100%), Mouse (83%), Cow (79%), Dog (82%), Guinea Pig (75%), Horse (86%), Pig (79%), Rabbit (79%), Rat (83%), Yeast (77%), and Zebrafish (85%) .

  • For species-specific studies, select antibodies validated for your particular species or with highest sequence homology.

• Epitope analysis and validation:

  • Perform sequence alignment of the epitope region across species of interest.

  • Validate antibodies in each species individually before comparative studies.

  • Use blocking peptides specific to each species to confirm specificity.

• Controls for cross-species studies:

  • Include MRPL36 knockout or knockdown samples from each species being studied.

  • Use recombinant MRPL36 proteins from different species as positive controls.

  • When possible, run simultaneous samples from multiple species to directly compare band patterns and sizes.

• Optimization of experimental conditions:

  • Adjust antibody concentrations for each species based on sequence homology.

  • Modify stringency of washing conditions based on the degree of cross-reactivity observed.

  • Consider using higher affinity purified antibodies for challenging species.

• Alternative approaches for highly divergent species:

  • Consider epitope-tagging approaches for species where antibody cross-reactivity is problematic.

  • For evolutionary studies, consider raising custom antibodies against conserved epitopes.

This strategic approach is particularly important when studying MRPL36's functional conservation across species, especially considering its role in mitochondrial translation that may have species-specific adaptations .

How should researchers interpret differences in MRPL36 expression patterns across tissues and disease states?

Interpretation of MRPL36 expression patterns requires careful consideration of several factors:

• Tissue-specific variation:

  • MRPL36 expression normally varies across tissues based on mitochondrial content and activity.

  • Established positive controls for MRPL36 detection include human testis and colon tissues .

  • When comparing tissues, normalize MRPL36 levels to mitochondrial content markers (e.g., VDAC, COX IV) rather than to total cellular proteins.

• Disease state interpretation:

  • Increased MRPL36 levels may indicate compensatory upregulation of mitochondrial translation machinery, as research has shown that overexpression can increase translation efficiency .

  • Decreased levels may suggest mitochondrial dysfunction or altered mitochondrial biogenesis.

  • Changes in MRPL36 localization (using immunofluorescence with conjugated antibodies like ABIN6078093) can indicate alterations in mitochondrial organization or stress .

• Domain-specific analysis:

  • Using domain-specific antibodies (N-terminal vs. C-terminal) can reveal processing differences or domain-specific degradation.

  • The C-terminal extension domain has distinct functions in translational regulation, so altered ratios of full-length to processed forms may have functional significance .

• Correlation with functional outcomes:

  • Changes in MRPL36 should be correlated with functional measures of mitochondrial translation (e.g., synthesis rates of mtDNA-encoded proteins).

  • Research has demonstrated that MRPL36 affects assembly of respiratory chain complexes, so expression changes should be interpreted in context of complex assembly efficiency .

• Genetic background considerations:

  • Interpretation should consider genetic background, as MRPL36 has been identified as a suppressor of specific cox2 mutants .

  • Different genetic backgrounds may show varying dependencies on MRPL36 for mitochondrial function.

These interpretive frameworks help distinguish pathological changes from normal variation and can guide hypothesis generation for mechanistic studies .

What approaches can differentiate between direct effects of MRPL36 dysfunction and secondary consequences on mitochondrial translation?

Differentiating primary from secondary effects of MRPL36 dysfunction requires methodical experimental approaches:

• Temporal analysis of molecular events:

  • Implement time-course studies using inducible MRPL36 knockdown or knockout systems.

  • Track the sequence of events following MRPL36 perturbation to establish causality.

  • Research has shown that absence of the CE domain leads first to decreased MRPL36 stability, followed by impaired translation product folding and assembly, and ultimately degradation of translation products .

• Domain-specific perturbations:

  • Compare effects of full MRPL36 knockout versus domain-specific deletions.

  • Research demonstrates that the L31 domain is necessary for basic respiratory and translational activity, while the CE domain affects translational regulation without abolishing basic function .

  • This approach helps separate MRPL36's structural role in ribosomes from its regulatory functions.

• Direct measurement of ribosome function:

  • Assess ribosome assembly using sucrose gradient fractionation to directly examine if MRPL36 perturbation affects ribosome integrity.

  • Measure peptidyl transferase activity in isolated ribosomes to determine if core translation functions are affected.

  • Research has shown that MRPL36 stabilizes the interaction between large and small ribosomal subunits, which can be directly measured .

• Rescue experiments:

  • Implement rescue experiments with wild-type MRPL36 or domain variants.

  • Time-dependent rescue can reveal which effects are reversible and which represent secondary adaptations.

  • The finding that the CE domain alone could suppress specific cox2 mutants highlights the value of this approach .

• Systems biology approach:

  • Combine proteomics, transcriptomics, and metabolomics to create a comprehensive picture of response networks.

  • Network analysis can help distinguish primary nodes (direct effects) from downstream consequences.

These approaches provide a framework for establishing causality and understanding the mechanisms by which MRPL36 dysfunction affects mitochondrial translation and subsequent cellular processes .

How can researchers reconcile contradictory findings between different experimental systems when studying MRPL36 function?

When faced with contradictory findings across experimental systems studying MRPL36, researchers should consider several methodological approaches to reconciliation:

This systematic approach allows researchers to determine whether contradictions represent methodological artifacts or biologically meaningful context-dependent functions of MRPL36 .

What emerging techniques could enhance the study of MRPL36's role in coordinating mitochondrial translation and respiratory chain assembly?

Several cutting-edge techniques hold promise for deeper investigation of MRPL36 function:

• Cryo-electron microscopy (Cryo-EM) of mitochondrial ribosomes:

  • High-resolution structural analysis of MRPL36 within intact mitochondrial ribosomes can reveal molecular interactions that mediate its role in stabilizing ribosomal subunit interactions .

  • Time-resolved Cryo-EM could capture conformational changes during different stages of translation.

• Single-molecule fluorescence resonance energy transfer (smFRET):

  • Applying smFRET to fluorescently labeled MRPL36 (using conjugated antibodies like ABIN6078093) can reveal dynamic interactions during translation .

  • This approach could elucidate how MRPL36 influences the accuracy and efficiency of protein synthesis.

• Proximity-dependent biotin identification (BioID) or APEX2 labeling:

  • These techniques can map the dynamic interactome of MRPL36 during different states of mitochondrial translation.

  • They could identify transient interaction partners involved in coordinating translation with respiratory chain assembly.

• CRISPR-based screening approaches:

  • Genome-wide CRISPR screens in cells with modified MRPL36 can identify genetic interactions and compensatory pathways.

  • Domain-specific CRISPR editing can create precise modifications to dissect the functions of specific MRPL36 regions.

• Ribosome profiling of mitochondrial translation:

  • Applying ribosome profiling specifically to mitochondrial ribosomes can reveal how MRPL36 influences translation dynamics at a transcriptome-wide level.

  • This could identify transcript-specific effects of MRPL36 on translation efficiency or accuracy.

• Integrative multi-omics approaches:

  • Combining proteomics, transcriptomics, and metabolomics in response to MRPL36 perturbations can provide a systems-level understanding of its role.

  • This approach could reveal previously unrecognized connections between mitochondrial translation and cellular metabolism.

These emerging techniques could transform our understanding of how MRPL36 coordinates mitochondrial translation with respiratory chain assembly, potentially opening new avenues for therapeutic interventions in mitochondrial disorders .

How might targeting MRPL36 contribute to therapeutic strategies for mitochondrial diseases?

MRPL36's critical role in mitochondrial translation and respiratory chain assembly suggests several potential therapeutic applications:

• Gene therapy approaches:

  • Delivering optimized MRPL36 variants could potentially rescue mitochondrial translation defects.

  • Research showing that overexpression of MRPL36 increases translation efficiency suggests potential benefit in conditions with impaired mitochondrial translation .

  • The finding that the CE domain alone could suppress specific cox2 mutants suggests domain-specific gene therapy approaches may be viable .

• Small molecule modulators:

  • Developing compounds that stabilize MRPL36-ribosome interactions could enhance mitochondrial translation fidelity.

  • Targeting the interaction between MRPL36 and other ribosomal components could modulate translation rates in diseases with aberrant mitochondrial protein synthesis.

• Peptide-based approaches:

  • Synthetic peptides mimicking the C-terminal extension domain could potentially modulate translation in a manner similar to the finding that this domain alone has functional effects .

  • These peptides could be designed to cross mitochondrial membranes using targeting sequences.

• Combination therapies:

  • MRPL36-targeted approaches could complement existing mitochondrial therapies that target other aspects of mitochondrial function.

  • Since MRPL36 affects the assembly of translation products into respiratory chain complexes, combining MRPL36 modulation with approaches that enhance complex stability could have synergistic effects .

• Biomarker applications:

  • MRPL36 levels or post-translational modifications could serve as biomarkers for mitochondrial translation efficiency.

  • Domain-specific antibodies could be used to detect altered processing or degradation patterns as diagnostic indicators .

• Precision medicine applications:

  • Given MRPL36's role as a suppressor of specific genetic defects, genotype-specific MRPL36 modulation could represent a precision medicine approach to mitochondrial disorders .

  • Screening for genetic backgrounds that would specifically benefit from MRPL36 modulation could guide therapeutic decisions.

These therapeutic directions require further research but represent promising avenues based on our current understanding of MRPL36 biology and the availability of specific antibodies and tools to study its function .